Sulfapyridine

Summary

Sulfapyridine (CHEMBL700) is an approved small-molecule antiinfective agent (ATC J01EB04); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01EB04
• Indications: 1 condition
• Chemistry: 249.29 Da · C11H11N3O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL700
Name	Sulfapyridine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5336
ChEBI	CHEBI:132842
ATC	J01EB04
Molecular formula	C11H11N3O2S
Molecular weight	249.29
InChIKey	GECHUMIMRBOMGK-UHFFFAOYSA-N

SMILES: C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-pyridin-2-ylbenzenesulfonamide

ChEBI definition: A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position.

Pharmacological roles (ChEBI): antiinfective agent, dermatologic drug, drug allergen.

Also known as: Concord 693, Coccoclase, Dagenan, Eubasin, NSC-41791, NSC-4753, Piridazol, Sulfapiridina, Sulfapyridine, Sulfanilamidopyridine, sulfapyridine, SID26746948

Parent form; salt/anhydrous children: CHEMBL2105500

Patent coverage: 2,219 distinct patent families (6,755 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,742 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Survival motor neuron protein, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, Beta-lactamase, Cruzipain.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q9F4F7	6.2	Potency	631	nM	CHEMBL_ACT_4372660
P25779	5.6	Potency	2512	nM	CHEMBL_ACT_3992268
P02791	5.2	Potency	6310	nM	CHEMBL_ACT_4477834

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 10 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).